Samsung BioLogics Announces New Head Of Global Business Development

News provided by

May 29, 2012, 06:00 ET

SEOUL, Korea, May 29, 2012 /PRNewswire/ -- Samsung BioLogics, a full-service biopharmaceutical contract development & cGMP manufacturing organization, has announced the appointment of Jeremy M. Caudill as Vice President of Global Business Development. In his new role, Mr. Caudill has relocated to Korea to join the Samsung BioLogics team and has global responsibilities for all business development & related activities.

Tae-Han Kim, Ph.D., CEO of Samsung BioLogics says: "Jeremy brings an exceptional track record of business development in the biopharmaceutical market combined with an extensive network of senior level decision makers. He is an industry leader and brings to Samsung BioLogics an impressive background including broad international experience in business development, which will support us in selling the services of our state-of-the-art 30,000 L plant in Songdo, Korea."

Mr. Caudill has over 15 years of experience in the biopharmaceutical industry.

He joins Samsung BioLogics from Oncobiologics, Inc. where he served most recently as Vice President, Strategic Business Development with previous positions at DSM Biologics where he was Global Vice President of Sales, Marketing and Business Development, Lonza and Sigma-Aldrich. He earned a B.S. in Biological Sciences from Indiana University.

For more information, please contact Samsung BioLogics at: [email protected]

About Samsung
Samsung is composed of companies in a wide range of business from consumer electronics to finance and insurance. Samsung was founded in 1938, and its revenue in 2010 was 255 trillion won ($220 billion). In May 2010, Samsung announced the biopharmaceutical sector as one of five new strategic businesses that would lead the group's future growth, committing to invest 2.1 trillion won ($2 billion) in biopharmaceuticals by 2020. For more information about the company, please visit www.samsung.com

Samsung Disclaimer
This press release may contain certain forward-looking statements that reflect our current views and expectations with respect to our performance, businesses, and future events. Please understand that these statements are subject to a number of risks, uncertainties, and assumptions, any of which could cause actual results to materially differ from the plans, objectives, expectations, estimates, and intentions we express. In no event will we or any of our subsidiaries, affiliates, directors, officers, agents, or employees be liable before any third party, including investors, for any investment or business decision made or action taken based on information and statements contained in this press release or for any consequential, special, or similar damages.

SOURCE Samsung BioLogics